References
- Atkins W. M., Wang R. G., Lu A. Y.H. Allosteric behavior in cytochrome p450‐dependent in vitro drug–drug interactions: a prospective based on conformational dynamics. Chem. Res. Toxicol. 2001; 14: 337–338
- Banci L., Bertini I., Marconi S., Pierattelli R., Sligar S. G. Cytochrome P450 and aromatic bases: a 1H NMR study. J. Am. Chem. Soc. 1994; 116(11)4866–4873
- Cupp‐Vickery J., Anderson R., Hatziris Z. Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc. Natl. Acad. Sci. U. S. A. 2000; 97(7)3050–3055, [CROSSREF], [CSA]
- Dabrowski M. J., Schrag M. L., Wienkers L. C., Atkins W. M. Pyrene–pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J. Am. Chem. Soc. 2002; 124(40)11866–11867, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Davydov D. R., Kumar S., Halpert J. R. Allosteric mechanisms in P450eryF probed with I‐Pyrenebutanol: a novel fluorescent substrate. Biochem. Biophys. Res. Commun. 2002; 294: 806–812, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Egnell A. C., Houston B., Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J. Pharmacol. Exp. Ther. 2003; 305(3)1251–1262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Guengerich F. P. Cytochrome P‐450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 1–317, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Guengerich F. R., Johnson W. W. Kinetics of ferric cytochrome P450 reduction by NADPH‐cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. Biochemistry 1997; 36: 14724–14750, [CROSSREF]
- Hlavica P., Lewis D. F.V. Allosteric phenomena in cytochrome P450‐catalyzed monooxygenations. Eur. J. Biochem. 2001; 268: 4817–4832, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Houston J. B., Kenworthy K. E. In vitro–in vivo scaling of CYP kinetic data not consistent with the classical michaelis‐menten model. Drug Metab. Dispos. 2000; 28: 246–254, [PUBMED], [INFOTRIEVE], [CSA]
- Hosea N. A., Miller G. P., Guengerich F. P. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 2000; 39: 5929–5939, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hutzler J. M., Wienkers L. C., Wahlstrom J. L., Carlson T. J., Tracy T. S. Activation of cytochrome P450 2C9‐mediated metabolism: mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 2003; 410(1)16–24, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Khan K. K., He Y. A., He Y. Q., Halpert J. R. Site‐directed mutagenesis of cytochrome P450eryF: implications for substrate oxidation, cooperativity, and topology of the active site. Chem. Res. Toxicol. 2002; 15(6)843–853, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Korzekwa K. R., Krishnamachary N., Shou M., Ogai A., Parise R. A., Rettie A. E., Gonzalez F. J., Tracey T. S. Evaluation of atypical cytochrome P450 kinetics with two‐substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137–4147, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lasker J. M., Huang M. T., Conney A. H. In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J. Pharmacol. Exp. Ther. 1984; 229(1)162–170, [PUBMED], [INFOTRIEVE]
- Lian L. Y., Barsukov I. L., Sutcliffe M. J., Sze K. H., Roberts G. C. Protein–ligand interactions: exchange processes and determination of ligand conformation and protein–ligand contacts. Methods Enzymol. 1994; 239: 657–700, [PUBMED], [INFOTRIEVE]
- Maenpaa J., Hall S. D., Ring B. J., Strom S. C., Wrighton S. A. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha‐naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998; 8(2)137–155, [PUBMED], [INFOTRIEVE], [CSA]
- Ost T. W.B., Clark J., Mowat C. G., Miles C. S., Walkinshaw M. D., Reid G. A., Chapman S. K., Daff S. Oxygen activation and electron transfer in flavocytochrome P450 BM3. J. Am. Chem. Soc. 2003; 125: 15010–15020, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pochapsky S. S., Pochapsky T. C. Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition. Curr. Top. Med. Chem. 2001; 1(5)427–441, [PUBMED], [INFOTRIEVE], [CSA]
- Poli‐Scaife S., Attias R., Dansette P. M., Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry 1997; 36(42)12672–12682, [CROSSREF]
- Rock D. A., Perkins B. N., Wahlstrom J., Jones J. P. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy omega product formation. Arch. Biochem. Biophys. 2003; 416(1)9–16, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rodriguez‐Mias R. A., Pellecchia M. Use of selective Trp side chain labeling to characterize protein–protein and protein–ligand interactions by NMR spectroscopy. J. Am. Chem. Soc. 2003; 125(1)2892–2893, [CROSSREF]
- Shou M., Grogan J., Mancewicz J. A., Krausz K. W., Gonzalez F. J., Gelboin H. V., Korzekwa K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33(21)6450–6455, [PUBMED], [INFOTRIEVE]
- Shou M., Dai R., Cui D., Korzekwa K. R., Baillie T. A., Rushmore T. H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 2001; 276(3)2256–2262, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Shou M., Lin Y., Lu P., Tang C., Mei Q., Cui D., Tang W., Ngui J. S., Lin C. C., Singh R., Wong B. K., Yergey J. A., Lin J. H., Pearson P. G., Baillie T. A., Rodrigues A. D., Rushmore T. H. Enzyme kinetics of cytochrome P450‐mediated reactions. Curr. Drug Metab. 2001; 2: 17–36, [PUBMED], [INFOTRIEVE]
- Schwab G. E., Raucy J. L., Johnson E. F. Modulation of rabbit and human hepatic cytochrome P‐450‐catalyzed steroid hydroxylations by alpha‐naphthoflavone. Mol. Pharmacol. 1988; 33(5)493–499, [PUBMED], [INFOTRIEVE]
- Tang W., Stearns R. A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug–drug interactions. Curr. Drug Metab. 2001; 2: 185–198, [PUBMED], [INFOTRIEVE]
- Tracy T. S. Atypical enzyme kinetics: their effect on in vitro–in vivo pharmacokinetic predictions and drug interactions. Curr. Drug Metab. 2003; 4(5)341–346, [PUBMED], [INFOTRIEVE]
- Ueng Y., Kuwabara T., Chun Y., Guengerich F. P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997; 36: 370–381, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wang R. W., Newton D. J., Liu N., Atkins W. M., Lu A. Y. Human cytochrome P‐450 3A4: in vitro drug–drug interaction patterns are substrate‐dependent. Drug Metab. Dispos. 2000; 28(3)360–366, [PUBMED], [INFOTRIEVE], [CSA]